ABUS Arbutus Biopharma Corporation - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ABUS Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$3.98
Analyst Target
$5.77
+45.1%
Upside
52W High
$5.1
52W Low
$2.71
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 14, 2026
Market cap
$765.45M
P/E
N/A
ROE
-45.9%
Profit margin
-289.4%
Debt/Equity
0.06
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ABUS exhibits severe financial distress signals, with a Piotroski F-Score of 0/9 indicating extreme operational weakness and no signs of financial stability. The company reports massive negative margins, negative ROE and ROA, and a 60.5% year-over-year revenue decline, reflecting deteriorating business fundamentals. Despite a strong recent earnings surprise (25.11% average), the underlying trajectory shows declining profitability and unsustainable losses. The absence of a Graham Number and intrinsic value, combined with a price-to-sales ratio of 52.41, suggests the stock is trading at a significant premium relative to fundamentals. Insider activity remains neutral, offering no confidence signal.
Key Strengths
Recent quarterly earnings have shown positive surprises (e.g., +115.2% in Q2 2025)
Strong cash position relative to debt (Current Ratio: 18.80, Quick Ratio: 18.31)
Low debt-to-equity ratio (0.06), indicating minimal leverage risk
Analyst target price ($5.77) implies upside potential from current levels
Historical earnings growth has shown volatility with occasional strong beats
Key Risks
Piotroski F-Score of 0/9 signals severe financial distress and operational failure
Negative profit margins (-289.45%) and operating margins (-1567.67%) indicate unsustainable business model
60.5% YoY revenue decline reflects shrinking top-line performance
No positive free cash flow or operating cash flow data available, suggesting cash burn
No dividend, no payout history, and no intrinsic value estimate make valuation speculative
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
18
Weak
20
35
25
10
0
AI Verdict
High Risk
Key drivers: Piotroski F-Score of 0, Negative profitability across all metrics, Declining revenue and earnings, No financial health indicators beyond liquidity
Confidence
90%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Low debt-to-equity ratio (0.06)
- High current and quick ratios (18.80, 18.31)
Watchpoints
- Price/Sales of 52.41 is extremely high
- No Graham Number or intrinsic value
- Negative earnings preclude P/E and PEG use
Future
35/100
Ref Growth rates
Positives
- Recent positive earnings surprises (25.11% avg)
- Analyst target price of $5.77 suggests upside
Watchpoints
- 60.5% YoY revenue decline
- Negative earnings growth (forward P/E: -23.61)
- No clear path to profitability
Past
25/100
Ref Historical trends
Positives
- Historical earnings beats (e.g., +115.2% in Q2 2025)
- Some quarters showed strong EPS performance
Watchpoints
- Consistent negative earnings over 25 quarters
- Most recent Q/Q EPS growth: -700.0%
- Declining trend in revenue and profitability
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Extremely high current and quick ratios
- Very low debt-to-equity (0.06)
Watchpoints
- Piotroski F-Score of 0/9 (severe distress)
- No Altman Z-Score available, but F-Score implies high bankruptcy risk
- Negative ROE (-45.88%) and ROA (-16.46%)
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout
- Payout ratio: 0.00%
- Dividend strength: 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.98
Analyst Target
$5.77
Upside/Downside
+45.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ABUS and closest competitors.
Updated 2026-02-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ABUS
Arbutus Biopharma Corporation
Primary
|
-11.4% | +46.9% | +20.6% | +18.1% | -16.7% | +3.6% |
|
BGM
BGM Group Ltd.
Peer
|
-90.8% | -38.2% | -66.0% | -64.4% | -12.5% | 0.0% |
|
AMN
AMN Healthcare Services, Inc.
Peer
|
-72.8% | -78.8% | -26.3% | +3.5% | +28.0% | +7.7% |
|
AHG
Akso Health Group
Peer
|
-40.6% | +246.5% | +7.2% | -12.9% | +8.0% | +4.9% |
|
BBNX
Beta Bionics, Inc.
Peer
|
-32.5% | -32.5% | -32.5% | +7.5% | -48.7% | -13.7% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-23.61
PEG Ratio
N/A
P/B Ratio
9.88
P/S Ratio
52.41
EV/Revenue
46.31
EV/EBITDA
-22.05
Market Cap
$765.45M
Profitability
Profit margins and return metrics
Profit Margin
-289.45%
Operating Margin
-1567.68%
Gross Margin
-98.86%
ROE
-45.88%
ROA
-16.46%
Growth
Revenue and earnings growth rates
Revenue Growth
-60.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.06
Low debt
Current Ratio
18.8
Strong
Quick Ratio
18.31
Excellent
Cash/Share
$0.49
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-26
$N/A
2025-11-13
$-0.06
-21.8% surprise
2025-08-06
$0.01
+115.2% surprise
2025-05-14
$-0.18
-18.1% surprise
Healthcare Sector Comparison
Comparing ABUS against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
Return on Equity (ROE)
-45.88%
This Stock
vs
-56.84%
Sector Avg
-19.3%
(Below Avg)
Profit Margin
-289.45%
This Stock
vs
-20.8%
Sector Avg
+1291.8%
(Superior)
Debt to Equity
0.06
This Stock
vs
2.68
Sector Avg
-97.8%
(Less Debt)
Revenue Growth
-60.5%
This Stock
vs
61.93%
Sector Avg
-197.7%
(Slower)
Current Ratio
18.8
This Stock
vs
3.47
Sector Avg
+442.3%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ABUS
Arbutus Biopharma Corporation
|
BEARISH | $765.45M | - | -45.9% | -289.4% | $3.98 | |
|
BGM
BGM Group Ltd.
|
BEARISH | $746.32M | - | -16.5% | -26.3% | $3.72 | |
|
AMN
AMN Healthcare Services, Inc.
|
BEARISH | $787.1M | - | -35.9% | -10.1% | $20.49 | |
|
AHG
Akso Health Group
|
BEARISH | $818.31M | - | -80.3% | -% | $1.49 | |
|
BBNX
Beta Bionics, Inc.
|
BEARISH | $702.63M | - | -47.5% | -87.9% | $15.96 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-02 | Androski (Lindsay J.D.) | Senior Officer of Issuer | Stock Award | 28,000 | - |
| 2026-02-02 | Nguyen (Tuan) | Senior Officer of Issuer | Stock Award | 73,500 | - |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
3 analysts
Chardan Capital
2025-11-14
Buy
Buy
Past News Coverage
Recent headlines mentioning ABUS from our newsroom.
Newest → oldest
No matching news yet.